<DOC>
	<DOCNO>NCT00871936</DOCNO>
	<brief_summary>The purpose study determine whether SLx-4090 combination metformin therapy reduce HbA1c patient Type 2 Diabetes effectively metformin therapy alone .</brief_summary>
	<brief_title>A Comparison SLx-4090 Combination With Metformin Versus Metformin Therapy Alone Patients With Type 2 Diabetes</brief_title>
	<detailed_description>1 . HbA1c 12 week 2 . FPG 12 week 3 . Safety tolerability 4 . Plasma level SLx-4090</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>HbA1c 711 % On stable dose metformin least 6 week Type 1 Diabetes Antidiabetic medication addition metformin FPG &gt; 270 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>